Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnevist Dosing in Peripheral MRA
NCT00652418Phase 2Completed
- Sponsor
- Bayer
- Start
- Jul 2004
- Primary completion
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of gadopentetate dimeglumine in Peripheral Arterial Disease (PAD) (2 arms), sponsored by Bayer. Primary endpoint: Diagnostic ability. Started Jul 2004; status: completed.
02
Drugs
gadopentetate dimeglumine
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT00652418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00652418.